Terence Friedlander News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Wave of Antibody-Drug Conjugates Poised to Change Treatment Paradigms Across Multiple Cancers

Wave of Antibody-Drug Conjugates Poised to Change Treatment Paradigms Across Multiple Cancers
ajmc.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ajmc.com Daily Mail and Mail on Sunday newspapers.

San franciscoUnited statesMayo clinic in rochesterAstellas pharmaIan kropDaiichi sankyo adcsBradley mcgregorDana farber tarantinoVadims koshkinPaolo tarantinoJamie carrollTerence friedlanderTerrence friedlanderDaiichi sankyoGenentech rocheLank center

Revisit the Top 5 OncLive On Air Episodes of 2023

In case you missed it, here is a recap of the most popular episodes of OncLive On Air® from 2023.

United statesNational taiwan university hospitalT ai peiFrance generalUniversity of chicagoSan antonioNew yorkDana farber cancer instituteRegion flamandeInstitut curieFrancois clement bidardPatrick borgenTerence friedlanderLisaa careyArielle medfordConstantine tam

First-line Enfortumab Vedotin Plus Pembrolizumab Has Durable Activity in Urothelial Carcinoma

Responses achieved with enfortumab vedotin plus pembrolizumab were found to be rapid and durable in patients with previously untreated locally advanced or metastatic urothelial carcinoma who were cisplatin ineligible.

San franciscoUnited statesAstellas pharmaGenentech rocheRoche genentechAstrazeneca medimmuneBristol myers squibbTerence friedlanderUniversity of californiaCancer researchHelen diller family comprehensive cancer centerDivision of hematology oncologyFoundation medicineAffairs incZuckerberg san francisco generalDava oncology

FDA Approval Insights: Enfortumab Vedotin Plus Pembrolizumab in Urothelial Carcinoma

Dr Friedlander discusses the FDA approval of enfortumab vedotin plus pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma, key efficacy and safety data from the EV-103 trial, and the importance of incorporating this regimen into the frontline setting for this population.

Terence friedlanderAshling wahnerDivision of hematology oncologyCancer research at zuckerberg san franciscoHelen diller family comprehensive cancer centerUniversity of california san franciscoCancer researchZuckerberg san francisco generalCalifornia sanOnclive on airOnclive stateScience summitApple podcastsGoogle podcastsAmazon musicFda approval of enfortumab vedotin plus pembrolizumab

Enfortumab Vedotin With Pembrolizumab May Usher in New Standard for Treatment of Urothelial Carcinoma

Terence Friedlander, MD, discusses the significance of the FDA approval of enfortumab vedotin combined with pembrolizumab for patients with locally advanced or metastatic urothelial carcinoma, and expands on the data from the EV-103/KEYNOTE-869 trial that supported the approval.

San franciscoUnited statesTerence friedlanderCancer researchHelen diller family comprehensive cancer centerUniversity of californiaDivision of hematology oncologyZuckerberg san francisco generalEnfortumab vedotinLocally advanced or metastatic urothelial carcinomaEv 103 keynote 869